Allogeneic hematopoietic stem cell transplantation is a treatment mainly used for blood-related cancers and some other severe diseases. During this process, stem cells from healthy donors are transferred into patient's bodies to replace damaged or diseased cells. While this treatment can be life-saving, it comes with serious risks and complications like GVHD.

GVHD is a complex medical condition that often occurs after allogeneic hematopoietic stem cell transplantation. Thereby, the donated stem cells perceive the recipient's body as foreign and initiate an immune response against it, which leads to severe complications and prevents a broader application of these transplantations. 

We have developed a targeted therapy designed to effectively modulate immune responses. This breakthrough not only has the potential to significantly reduce the risk of complications like GVHD, but also offers promise in treating a wide range of autoimmune and inflammatory diseases. By fine-tuning the immune system's behavior, our solution aims to maximize the benefits of transplantation and other therapies, thereby improving patient outcomes and expanding the scope of treatable diseases.

ASH Therapeutics

Org chart

Teams

Offices